DiogenX strengthens its management team

The new Head of Development at DiogenX, Dr Hélène Sicard, has more than 25 years of experience in the development of different classes of drugs (antibodies, small molecules, cell therapies) in various therapeutic areas. She has been involved in bringing more than ten molecules from preclinical to early clinical phase and has extensive experience in late-stage drug development. Hélène Sicard has actively participated in the creation of several biotech companies and in their strategic and structural growth. Sicard holds a PhD in molecular biology from the Paul Sabatier University in Toulouse (France).

The French company also welcomes Laetitia Cohen-Tannoudji as Senior Director, CMC, and Joanna Fares as Director of Drug Development Sciences. Both previously worked for Emergence Tx (now a wholly owned subsidiary of Eli Lilly and Company) and before that for Innate Pharma. In addition, Renaud Perret joins the team as Director of Administration and Finance. He previously worked at Invectys for 16 years and before that at GSK.